Q1 Revenue Up 12% to $264.8M, Net Income Nearly Triples to $20.9M
INNV has more than doubled off its 52-week low of $3.935.
Summary
InnovAge opened fiscal 2027 with revenue of $264.8M, up 12.1% from $236.1M a year ago, and net income of $20.9M versus $7.7M — EPS of $0.14 against $0.06. Adjusted EBITDA nearly doubled to $31.3M (11.8% margin) from $17.6M (7.5%), and center-level contribution margin rose to 24.0% from 21.8%. Census grew to roughly 8,420 participants from 7,890. The company confirmed, rather than raised, its fiscal 2027 guidance of $1.050B-$1.085B revenue and $105M-$115M Adjusted EBITDA, so the beat is in the quarter, not the outlook. This follows the September 8 disclosure of 16% fiscal 2026 revenue growth to $989.7M with a $37M litigation accrual still hanging over the balance sheet. Cash stands at $119.3M plus $43.7M in short-term investments against $61.4M of debt. The 5:00 PM ET call is the next checkpoint for margin durability and any commentary on the shift to year-over-year comparisons.
At the time of this announcement, INNV was trading at $8.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.94 to $12.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.